A new report from researchers at Massachusetts General Hospital in Boston confirms what many scientists have long believed – that no type of asbestos is “safe” and that all can lead to malignant mesothelioma. In a study of 62 malignant peritoneal mesothelioma patients published in the American Journal of Industrial Medicine, the researchers found that more than a quarter of the cases of diffuse peritoneal … Continue reading Mesothelioma Report Shows All Types of Asbestos Can Be Lethal»

Extrapleural pneumonectomy, the most radical – and risky – type of surgery for malignant pleural mesothelioma, is more likely to lead to long term survival when paired with strategic follow-up treatments. That is the conclusion of researchers at Japan’s Kyushu University who conducted a retrospective study of 10 mesothelioma patients who underwent EPP at their institution between 2001 to 2010. EPP Surgery and Mesothelioma Outcomes … Continue reading Radical Surgery Alone Unlikely to Prolong Mesothelioma Survival»

The ratio of neutrophils to lymphocytes – a way of measuring inflammation in the body of people with malignant pleural mesothelioma – may help doctors predict how well they will respond to treatment. That is the conclusion of mesothelioma researchers at China’s Sichuan University. In a new article in the journal Oncotarget, the team observed that NLR has been associated with survival in other types … Continue reading Inflammation Marker May Predict Mesothelioma Prognosis»

The bright yellow chemical that gives turmeric its spicy kick has scored yet another win as a possible treatment for malignant mesothelioma. This time, scientists used it on lab rats to successfully shrink one of the most aggressive types of mesothelioma tumors. The plant polyphenol curcumin has been the subject of numerous malignant mesothelioma studies in recent years, in part because of its powerful anti-inflammatory properties. Curcumin as … Continue reading Curcumin Shrinks Aggressive Mesothelioma Tumors in New Study»

Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival»

The majority of mesothelioma patients polled say they could breathe easier after a procedure to remove excess lung fluid from their chest. The more fluid that was removed, the better they felt. Those findings come from a new UK study of patient-reported outcome measures among 158 people suffering from malignant pleural mesothelioma. Collecting Data from Mesothelioma Patients The data that formed the basis of the … Continue reading Fluid Drainage Brings Symptom Relief for Mesothelioma Patients»

City dwellers are no more likely to contract malignant pleural mesothelioma from asbestos dust in the air than people who live in rural areas – even though there is more asbestos dust in cities. That is the conclusion of a new study published in the journal Risk Analysis. The study was based on the fact that so-called “ambient asbestos”, or asbestos fibers that are free … Continue reading Mesothelioma Incidence Unaffected by Ambient Asbestos in Cities»

An international study of malignant mesothelioma suggests that deaths from the asbestos cancer have increased in recent years, in spite of advances in diagnostic and treatment tools. The study included data and estimates on deaths from malignant mesothelioma in 230 countries between 1994 and 2014. Based on information obtained from the World Health Organization, a team of scientists in Japan, Australia, Singapore, Thailand, the US, … Continue reading The World’s Workers Still Dying From Malignant Mesothelioma»

A new study of former South African mine workers suggests that too many asbestos-related diseases may be going undiagnosed. The study conducted by researchers at the University of the Witwatersrand and the National Institute for Occupational Health in Johannesburg found that, in a cohort of 149 workers, more than half of the cases of malignant mesothelioma were missed until after the patient had died. With … Continue reading Miner Study Finds Mesothelioma Often Undiagnosed»

The largest analysis of mesothelioma surgery ever done finds little survival difference between lung-sparing and lung-removing surgeries. A team of top mesothelioma oncologists and surgeons at three US Universities analyzed the cases of 1,307 malignant mesothelioma patients from the National Cancer Database (NCDB), a joint project of the American College of Surgeons and the American Cancer Society. After using a series of statistical tools to … Continue reading New Research Finds Little Survival Difference Between Mesothelioma Surgeries»

Disclaimer

Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly, Inc. All of the information provided on this website or by an employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.